A Comprehensive Review of Treatment Options of OSMF along with Future Developments
Published: 2023-10-20
Page: 334-341
Issue: 2023 - Volume 6 [Issue 1]
Neehal Kanojiya
*
Sri Aurobindo College of Dentistry Indore, M.P. India.
Kirti Gautam
Sri Aurobindo College of Dentistry Indore, M.P. India.
Pooja Mahay
Sri Aurobindo College of Dentistry Indore, M.P. India.
*Author to whom correspondence should be addressed.
Abstract
Oral potentially malignant disorders(opmds) are defined by WHO as “the risk of malignancy being present in a lesion or condition either at the time of initial diagnosis or at a future date.” OSMF(oral submucous fibrosis) being an opmd carries a very high chance of cancer if left untreated or undiagnosed in the long run. However there are no definitive guidelines for the treatment of osmf ranging from conservative(non invasive) options to radical surgical options. The primary objective of this article was to critically analyse the studies regarding the treatment options for osmf and to provide the clinician in a comprehensive manner all the available options in one place. A thorough electronic search was carried for relevant articles published until January 2022. Thirty two studies were included in this review after initial screening of 340 articles. The review found that inspite of there being so many available treatment options for osmf no sole therapy can be successfully advocated for the complete resolution of the disease therefore the clinician should rely on a combination of treatment options to achieve good results along with improving patient outcomes and overall quality of life thereby significantly reducing morbidity and mortality among patients suffering from osmf.
Keywords: HBOT, hyaluronidase, interferon gamma, osmf, pedicled flaps, reduced mouth opening, steroids
How to Cite
Downloads
References
Pindborg JJ, Sirsat SM. Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol. 1966;22(6):764–79.
Thakur N and Kumar V. An outline of existing clinical classification system for oral submucous fibrosis. J Res Adv Dent 2014;3(2):72-5.
More CB, Gupta S, Joshi J and Varma SN. Classification system for oral submucous fibrosis. J Indian Acad Oral Med Radiol 2012;24(1):24-9.
Khanna JN, Andrade NN. Oral submucous fibrosis: A new concept in surgical managementReport of 100 cases. Int J Oral MaxillofacSurg. 1995;24:433-9.
Gupta H, Grover N, Tyagi N, Misra A. Classification systems in oral submucous fibrosis patients: a review. TMU J Dent. 2018;2:13-9.
More CB, Gupta S, Joshi J, Varma SN. Classification system for oral submucous fibrosis. Journal of Indian Academy of Oral Medicine and Radiology. 2012;24(1): 24.
Hastak K, Lubri N, Jakhi SD, More C, John A, Ghaisas SD, Bhide SV. Effect of turmeric oil and turmeric oleoresin on cytogenetic damage in patients suffering from oral submucous fibrosis,CancerLetters. 1997;116(2).
Pipalia PR, Annigeri RG, Mehta R. Clinicobiochemical evaluation of turmeric with black pepper and nigella sativa in management of oral submucous fibrosis-a double-blind, randomized preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(6):705-712. DOI: 10.1016/j.oooo.2016.07.023. Epub 2016 Aug 6. PMID: 27720650.
Alam S, Ali I, Giri KY, Gokkulakrishnan S, Natu SS, Faisal M, Agarwal A, Sharma H. Efficacy of aloe vera gel as an adjuvant treatment of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(6):717-24. DOI: 10.1016/j.oooo.2013.08.003. PMID: 24237724.
Maher R, Aga P, Johnson NW, Sankaranarayanan R, Warnakulasuriya S. Evaluation of multiple micronutrient supplementation in the management of oral submucous fibrosis in Karachi. Pakistan Nutr Cancer. 1997;27(1):41–7.
Minden-Birkenmaier BA, Cherukuri K, Smith RA., Radic MZ., Bowlin GL. Manuka honey modulates the inflammatory behavior of a dHL-60 neutrophil model under the cytotoxic limit. Int. J. Biomater. 2019;6132581.
DOI: 10.1155/2019/6132581.
Sharma JK, Gupta AK, Mukhija RD, Nigam P. Clinical experience with the use of peripheral vasodilator in oral disorders. Int J Oral Maxillofac Surg. 1987;16(6):695-9. DOI: 10.1016/s0901-5027(87)80055-3. PMID: 3125268.
Borle RM, Borle SR. Management of oral submucous fibrosis: A conservative approach. J Oral Maxillofac Surg.
Sadaksharam J, Mahalingam S. Evaluation of Oral Pentoxifylline in the Management of Oral Submucous Fibrosis - An Ultrasonographic Study. Contemp Clin Dent. 2017;8(2):200-204. DOI: 10.4103/ccd.ccd_1192_16. PMID: 28839403; PMCID: PMC5551322.
Kumar A, Bagewadi A, Keluskar V, Singh M. Efficacy of lycopene in the management of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral RadiolEndod. 2007;103(2):207-13. DOI: 10.1016/j.tripleo.2006.07.011. Epub 2006 Oct 24. PMID: 17234537.
Tilakaratne WM, Ekanayaka RP, Herath M, Jayasinghe RD, Sitheeque M, Amarasinghe H. Intralesional corticosteroids as a treatment for restricted mouth opening in oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(2):224-31. DOI: 10.1016/j.oooo.2015.11.023. Epub 2016 Apr 19. PMID: 27422421.
Haque MF, Meghji S, Nazir R, Harris M. Interferon gamma (IFN-gamma) may reverse oral submucous fibrosis. J Oral Pathol Med. 2001;30(1):12-21. DOI: 10.1034/j.1600-0714.2001.300103.x. PMID: 11140895.
Goel S, Ahmed J. A comparative study on efficacy of different treatment modalities of oral submucous fibrosis evaluated by clinical staging in population of southern Rajasthan. J Cancer Res Ther. 2015;11(1):113–8.
Jiang X, Zhang Y, Li F, Zhu Y, Chen Y, Yang S, Sun G. Allicin as a possible adjunctive therapeutic drug for stage II oral submucous fibrosis: a preliminary clinical trial in a Chinese cohort. Int J Oral Maxillofac Surg. 2015;44(12):1540-6. DOI: 10.1016/j.ijom.2015.06.015. Epub 2015. PMID: 26165773.
Talsania JR, Shah UB, Shah AI, Singh NK. Use of diode laser in oral submucous fibrosis with trismus: prospective clinical study. Indian J Otolaryngol Head Neck Surg. 2009;61 (1):22-5. DOI: 10.1007/s12070-009-0012-x.
Epub 2009 Mar 21. PMID: 23120664; PMCID: PMC3450091.
Chaudhry Z, Gupta SR, Oberoi SS. The Efficacy of ErCr:YSGG Laser Fibrotomy in Management of Moderate Oral Submucous Fibrosis: A Preliminary Study. J Maxillofac Oral Surg. 2014;13(3): 286-94. DOI: 10.1007/s12663-013-0511-x.
Epub 2013 Apr 18. PMID: 25018602; PMCID: PMC4082553.
Sharma R, Thapliyal GK, Sinha R, Menon PS. Use of buccal fat pad in the treatment of oral submucous fibrosis. J Oral Maxillofac Surg; 2011.
Ambereen A, Bhutia O, Roychoudhury A, Yadav R, Khakhla DH, Vishwakarma K. Is Coronoidectomy Superior to Coronoidotomy for ImprovingMaximum Incisal Opening in Patients With Oral Submucous Fibrosis? J Oral Maxillofac Surg. 2021;79(4):863.e1-863.e7. DOI: 10.1016/j.joms.2020.11.009. Epub 2020 Dec 11. PMID: 33345813.
Rajkumar K, Roy Chowdhury SK, Vivek Saxena, Ramen Sinha,Superiorly based platysma myocutaneous flap for reconstruction of intra oral defect following fibrotomy in oral submucous fibrosis: Report of a case.
Kamath VV. Surgical Interventions in Oral Submucous Fibrosis: A Systematic Analysis of the Literature. J Maxillofac Oral Surg. 2015 Sep;14 (3):521-31.
DOI: 10.1007/s12663-014-0639-3. Epub 2014 Dec 25. PMID: 26225039; PMCID: PMC4510093.
Senthilkumar S, Chitra S, Vijayaraghavan RV. Hemaashree, Subhavani Effectiveness of Ultrasound Therapy on Oral Submucosal Fibrosis Indian Journal of Public Health Research & 3 Development, March 2020;11(03).
Patil PG, Hazarey V, Chaudhari R, Nimbalkar-Patil S. A randomized control trial measuring the effectiveness of a mouth-exercising device for mucosal burning in oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(6):713-718. DOI: 10.1016/j.oooo.2016.07.026. Epub 2016 Aug 6. PMID: 27720659.
Kumar MA, Radhika B, Gollamudi N, Reddy SP, Yaga US. Hyperbaric Oxygen Therapy-A Novel Treatment Modality in Oral Submucous Fibrosis: A Review. J Clin Diagn Res. 2015;9(5):ZE01-4. DOI: 10.7860/JCDR/2015/11500.5905. Epub 2015 May 1. PMID: 26155590; PMCID: PMC4484182.
More CB, Jatti Patil D, Rao NR. Medicinal management of oral submucous fibrosis in the past decade- A systematic review. J Oral Biol Craniofac Res. 2020;10(4):552-568. DOI: 10.1016/j.jobcr.2020.08.004.
Epub 2020 Aug 19. PMID: 32939334; PMCID: PMC7479289.
Zheng L, Guan ZJ, Pan WT, Du TF, Zhai YJ, Guo J. Tanshinone Suppresses Arecoline-Induced Epithelial-Mesenchymal Transition in Oral Submucous Fibrosis by Epigenetically Reactivating the p53 Pathway. Oncol Res. 2018;10;26(3):483-494. DOI:10.3727/096504017X14941825760362. Epub 2017 May 21. PMID: 28550687; PMCID: PMC7844836.
Suma GN, Arora MP, Lakhanpal M. Stem cell therapy: A novel treatment approach for oral mucosal lesions. J Pharm Bioallied Sci. 2015;7(1):2-8. DOI: 10.4103/0975-7406.149809. PMID: 25709329; PMCID: PMC4333622.